跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Efgartigimod
首页
药物
Efgartigimod
Efgartigimod
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
相关疾病
共 2 项相关疾病
generalized myasthenia gravis
chronic inflammatory demyelinating polyneuropathy
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Compositions and methods for treating immune thrombocytopenia
US 12202900 B2
申请人: ARGENX BV
优先权: 2018
CN
US
3 件公开
METHODS FOR TREATING PEMPHIGUS DISORDERS
EP 4454711 A3
申请人: ARGENX BV
优先权: 2020
EP
US
2 件公开
METHODS FOR TREATING CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
EP 4743114 A1
申请人: ARGENX BV
优先权: 2023
EP
WO
2 件公开
COMBINATION IMMUNOSUPPRESSION FOR INHIBITING AN IMMUNE RESPONSE AND ENABLING IMMUNOGEN ADMINISTRATION AND RE-ADMINISTRATION
US 20250242018 A1
申请人: REGENERON PHARMA
优先权: 2024
US
WO
2 件公开
METHODS FOR REDUCING PLATELET DEGRADATION USING FCRN ANTAGONISTS
WO 2025224506 A1
申请人: ARGENX BV
优先权: 2024
WO
INTRAVENOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
WO 2025233685 A1
申请人: ARGENX BV
优先权: 2024
WO
SUBCUTANEOUS FORMULATIONS, PRE-FILLED SYRINGES AND METHODS OF USE THEREOF
WO 2025233684 A1
申请人: ARGENX BV
优先权: 2024
WO
METHODS FOR TREATING MYOSITIS USING FCRN ANTAGONISTS
WO 2026109935 A1
申请人: ARGENX BV
优先权: 2024
WO
SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
US 20250388679 A1
申请人: ARGENX BV
优先权: 2025
US
药物
反馈